Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Maria Fernanda De La Rosa Flores is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by 1 distinct examiner, CRUM, MARY ABOU NADER, who is also identified as the busiest examiner for the portfolio. The prosecution is localized within 1 distinct art unit, which suggests a specialized focus for the company's current patent efforts. Having 1 pending office action means the applicant can focus entirely on the specific requirements of a single case. Because CRUM, MARY ABOU NADER is the sole examiner, the prosecution strategy does not need to account for varying examiner behaviors.
The concentration in 1 distinct art unit allows the applicant to monitor a specific set of examination trends within the Biotechnology & Pharmaceuticals field. With 1 pending office action, the administrative complexity is limited, facilitating a direct and efficient response process. CRUM, MARY ABOU NADER is responsible for 1 pending office action, making this examiner the primary gatekeeper for the company's current intellectual property goals. Practitioners can leverage this focus to build a consistent rapport with the examiner. The absence of other pending actions or examiners simplifies the management of the portfolio and reduces the risk of inconsistent arguments across different filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRUM, MARY ABOU NADER | 1 | 39.2% | +63.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274950 | MATRIX FORMULATED WITH PROBIOTICS FOR USE IN THE TREATMENT OF CARIES | CRUM, MARY ABOU NADER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274950 | MATRIX FORMULATED WITH PROBIOTICS FOR USE IN THE TREATMENT OF CARIES | CRUM, MARY ABOU NADER | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18274950 | MATRIX FORMULATED WITH PROBIOTICS FOR USE IN THE TREATMENT OF CARIES | CRUM, MARY ABOU NADER | 1657 | §103§112 | Non-Final OA | — | Pending | Jul 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMaria Fernanda De La Rosa Flores has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mary Abou Nader Crum has the most, with 1 of Maria Fernanda De La Rosa Flores's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
